Key Takeaways
- MAIA’s Phase 3 THIO-104 trial of ateganosine begins patient dosing for advanced NSCLC.
- The study will enroll up to 300 patients, comparing ateganosine with a checkpoint inhibitor to standard chemotherapy.
- Ateganosine has shown promising results, with a Fast Track designation from the FDA for non-small cell lung cancer treatment.
The biotechnology company MAIA has initiated the first patient dosing in its THIO-104 Phase 3 pivotal trial, evaluating ateganosine in combination with a checkpoint inhibitor (CPI) as a third-line treatment for advanced non-small cell lung cancer (NSCLC). This multicenter, open-label trial will randomize a maximum of 300 patients in a 1:1 ratio to receive either the ateganosine plus CPI treatment or the investigator’s choice of chemotherapy, with overall survival as the primary endpoint.
Regulatory approval has been secured to screen patients in Taiwan, Turkey, select European Medicines Agency (EMA) countries, and Georgia, and recruitment is currently in progress. MAIA aims to identify ateganosine as a new standard of care, leveraging prior results from the THIO-101 trial, which demonstrated a median progression-free survival (PFS) of 5.6 months compared to the standard 2.5 months for current treatments. Notably, one participant in the previous trial experienced a remarkable 30 months of survival.
Dr. Vlad Vitoc, the company’s CEO, expressed optimism about this milestone, highlighting their strategic approach to advancing ateganosine towards potential FDA approval. He anticipates that the Phase 3 trial will yield results consistent with previous Phase 2 findings, wherein patients showed median survival improvements from 6 months with conventional chemotherapy to 17.8 months with ateganosine.
Ateganosine, also referred to as THIO (6-thio-2’-deoxyguanosine), is designed to target telomeres, playing a critical role in cancer cell longevity and treatment resistance. Its unique mechanism promotes telomerase-dependent DNA damage, facilitating cancer cell death while stimulating both innate and adaptive immune responses. This characteristic positions ateganosine as a potentially transformative option for patients who have not benefited from existing therapies.
The FDA has granted Fast Track designation for ateganosine, signaling its potential for expedited review as a promising treatment for NSCLC. This designation may allow MAIA to bring this innovative therapy to the market more swiftly, potentially benefiting many patients facing advanced lung cancer.
Following this announcement, MAIA’s stock has seen a positive market reaction, rising by 9.09%. The company’s market capitalization has increased by approximately $5 million, illustrating significant investor interest. As of the latest updates, MAIA continues to monitor its stock performance alongside ongoing trials, in anticipation of the future impact of ateganosine therapy in the oncology landscape.
The content above is a summary. For more details, see the source article.